{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:33:51Z","timestamp":1790670831698,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1038\/ajg.2011.60","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T11:40:38Z","timestamp":1300189238000},"page":"674-684","source":"Crossref","is-referenced-by-count":385,"title":["Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review"],"prefix":"10.14309","volume":"106","author":[{"given":"Vincent","family":"Billioud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210306","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial.","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"R2-15-20210306","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"R3-15-20210306","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial.","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"R4-15-20210306","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ajg.2009.59","article-title":"Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohns disease: results from the CHARM trial.","volume":"104","author":"Colombel","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R5-15-20210306","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2007.05.006","article-title":"American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.","volume":"133","author":"Clark","year":"2007","journal-title":"Gastroenterology"},{"key":"R6-15-20210306","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohns disease: current management.","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R7-15-20210306","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohns disease: meta-analysis of placebo-controlled trials.","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-15-20210306","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohns disease: a critical systematic review.","volume":"15","author":"Cassinotti","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R9-15-20210306","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohns disease: a review.","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R10-15-20210306","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","article-title":"Safety and efficacy of adalimumab (D2E7) in Crohns disease patients with an attenuated response to infliximab.","volume":"100","author":"Papadakis","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R11-15-20210306","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1873-9954(08)70100-9","article-title":"P089 Adalimumab induction and maintenance: analysis of prescribed vs recommended doses among patients with Crohns disease in the United States.","volume":"2","author":"Mackowiak","year":"2008","journal-title":"J Crohns Colitis Suppl"},{"key":"R12-15-20210306","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial.","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"R13-15-20210306","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.14309\/00000434-201010001-01208","article-title":"Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohns disease: data from EXTEND.","volume":"105","author":"Sandborn","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R14-15-20210306","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ibd.21328","article-title":"Dosage adjustment during long-term adalimumab treatment for Crohns disease: clinical efficacy and pharmacoeconomics.","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R15-15-20210306","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","article-title":"Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohns disease.","volume":"31","author":"Panaccione","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-15-20210306","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2036.2007.03254.x","article-title":"Adalimumab maintenance therapy for Crohns disease with intolerance or lost response to infliximab: an open-label study.","volume":"25","author":"Peyrin-Biroulet","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-15-20210306","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/ajg.2009.509","article-title":"Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohns perineal fistulas.","volume":"104","author":"Ng","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R18-15-20210306","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohns disease.","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"R20-15-20210306","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0016-5085(09)60799-X","article-title":"Adalimumab in the treatment of active luminal and perianal Crohns disease: a single center experience in 100 patients.","volume":"136","author":"Rizzello","year":"2009","journal-title":"Gastroenterology"},{"key":"R21-15-20210306","doi-asserted-by":"crossref","first-page":"701-702","DOI":"10.1016\/S0016-5085(10)63226-X","article-title":"West RL, van Liere-Baron A et al. Previous non-response to infliximab predicts early dose-escalation in adalimumab treated Crohns disease patients.","volume":"138","author":"Bultman","year":"2010","journal-title":"Gastroenterology"},{"key":"R22-15-20210306","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5085(10)61510-7","article-title":"Adalimumab in the treatment of perianal Crohns disease: a single center in 64 patients.","volume":"138","author":"Gionchetti","year":"2010","journal-title":"Gastroenterology"},{"key":"R23-15-20210306","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/ajg.2009.372","article-title":"Efficacy of adalimumab in moderate-to-severe pediatric Crohns disease.","volume":"104","author":"Viola","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R24-15-20210306","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2036.2007.03583.x","article-title":"The use of adalimumab in the management of refractory Crohns disease.","volume":"27","author":"Ho","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-15-20210306","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohns disease.","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-15-20210306","first-page":"676","article-title":"Adalimumab induction and maintenance therapy for Crohns disease. An open-label study.","volume":"100","author":"Lopez Palacios","year":"2008","journal-title":"Rev Esp Enferm Dig"},{"key":"R28-15-20210306","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1365-2036.2008.03902.x","article-title":"Adalimumab for Crohns disease with intolerance or lost response to infliximab: a 3-year single-centre experience.","volume":"29","author":"Oussalah","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-15-20210306","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","article-title":"The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.","volume":"29","author":"Lees","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-15-20210306","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1873-9946(09)60069-6","article-title":"2 year follow up of adalimumab therapy in patients with Crohns disease.","volume":"3","author":"Kemp","year":"2009","journal-title":"J Crohns Colitis"},{"key":"R31-15-20210306","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0016-5085(09)63138-3","article-title":"Adalimumab in a clinical practiceexperience with human anti TNF-alpha therapy in tertiary clinical center.","volume":"136","author":"Bortlik","year":"2009","journal-title":"Gastroenterology"},{"key":"R32-15-20210306","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0016-5085(09)63007-9","article-title":"Predictors and timing of adalimumab (ADA) dose escalation in patients with Crohns disease (CD).","volume":"136","author":"Cohen","year":"2009","journal-title":"Gastroenterology"},{"key":"R33-15-20210306","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0016-5085(09)63016-X","article-title":"Anti-TNF therapy for Crohns disease: predictors of dose escalation and early discontinuation by 1 year of therapy.","volume":"136","author":"Naik","year":"2009","journal-title":"Gastroenterology"},{"key":"R34-15-20210306","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/ibd.21272","article-title":"Adalimumab for Crohns disease in clinical practice at Mayo clinic: the first 118 patients.","volume":"16","author":"Swoger","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"R35-15-20210306","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0016-5085(10)63216-7","article-title":"Persistency equals efficacy in adalimumab patients: preliminary report of a large single site experience.","volume":"138","author":"Wolf","year":"2010","journal-title":"Gastroenterology"},{"key":"R36-15-20210306","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0016-5085(10)63166-6","article-title":"Long-term durability of response to adalimumab treatment in Crohns disease.","volume":"138","author":"Chaparro","year":"2010","journal-title":"Gastroenterology"},{"key":"R37-15-20210306","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.14309\/00000434-201010001-01212","article-title":"Efficacy of adalimumab therapy in patients with Crohns disease who were unresponsive to or intolerant of infliximab: six years of experience in a single gastroenterology center.","volume":"105","author":"Shafran","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R38-15-20210306","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MPG.0b013e318174e886","article-title":"Safety and efficacy of adalimumab in pediatric patients with Crohn disease.","volume":"47","author":"Wyneski","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R39-15-20210306","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10620-009-0791-7","article-title":"Adalimumab treatment in children with refractory Crohns disease.","volume":"55","author":"Rosenbach","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R40-15-20210306","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2036.2008.03919.x","article-title":"Efficacy and complications of adalimumab treatment for medically-refractory Crohns disease: analysis of nationwide experience in Scotland (2004-2008).","volume":"29","author":"Ho","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R41-15-20210306","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2009.04130.x","article-title":"The efficacy and safety of a third anti-TNF monoclonal antibody in Crohns disease after failure of two other anti-TNF antibodies.","volume":"31","author":"Allez","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-15-20210306","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000253855","article-title":"Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohns disease.","volume":"81","author":"Nichita","year":"2010","journal-title":"Digestion"},{"key":"R43-15-20210306","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MEG.0b013e32832b20d4","article-title":"Survey on the use of adalimumab as maintenance therapy in Crohns disease in England and Ireland.","volume":"22","author":"Russo","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R44-15-20210306","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0016-5085(10)63203-9","article-title":"Long term efficacy of the second biologic in the management of Crohns disease. A retrospective survey on an English-Irish cohort.","volume":"138","author":"Russo","year":"2010","journal-title":"Gastroenterology"},{"key":"R45-15-20210306","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0016-5085(10)63204-0","article-title":"Adalimumab for luminal and perianal Crohns disease in real practice: a long-term multicenter study of effectiveness, safety and predictors of response.","volume":"138","author":"Ormaechea","year":"2010","journal-title":"Gastroenterology"},{"key":"R46-15-20210306","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/ajg.2009.493","article-title":"Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohns disease.","volume":"104","author":"Rosh","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R47-15-20210306","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0016-5085(09)60791-5","article-title":"Dosage pattern of adalimumab in real-world clinical practice and predictors of dosage increase in patients with Crohns disease in the US.","volume":"136","author":"Loftus","year":"2009","journal-title":"Gastroenterology"},{"key":"R48-15-20210306","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.14309\/00000434-200910003-01281","article-title":"Observational study of treatment patterns in patients newly initiated with adalimumab or infliximab therapy for Crohns disease.","volume":"104","author":"Plevy","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R49-15-20210306","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.14309\/00000434-200910003-01280","article-title":"Predictors of clinical response and maintenance of response in Crohns disease: data from CHARM.","volume":"104","author":"Rubin","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R50-15-20210306","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrgastro.2009.220","article-title":"The potential for disease modification in Crohns disease.","volume":"7","author":"Van Assche","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R51-15-20210306","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ajg.2008.38","article-title":"Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.","volume":"104","author":"Romberg-Camps","year":"2009","journal-title":"Am J Gastroenterol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg201160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201160","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:35:47Z","timestamp":1786541747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2011.60","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}